Collaboration | StoneWise Partners with Chipscreen Biosciences to Build an End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery
On November 19, 2025, Beijing StoneWise Technology Co., Ltd. announced the official launch of a collaboration with Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Code: 688321.SH) based on the MolVado AI 3D Molecular Generation and Small Molecule Drug Design Platform. Under the collaboration agreement, StoneWise will provide Chipscreen Biosciences with an engineering-oriented AI solution comprising a molecular generation model, a suite of AIDD (AI-aided Drug Discovery) computational tools, and a computing infrastructure to support its exploration and optimization efforts in the small molecule drug R&D phase.
As a pioneer in China's original innovative drug sector, Chipscreen Biosciences brings together a team of top-tier scientists with extensive experience in relevant fields. Leveraging an integrated technology platform combining AI-assisted design and chemogenomics, the company has successfully developed two First-in-class and Best-in-class original innovative drugs: Chidamide (for tumors) and Chiglitazar Sodium (for Type 2 diabetes). These drugs are marketed globally for multiple indications, and Chipscreen has laid out a portfolio of R&D projects with differentiated advantages and global competitiveness in areas such as malignant tumors, metabolic diseases, autoimmune diseases, and neurodegenerative diseases. The launch of this collaboration represents another strategic exploration by both parties in advancing the digital R&D toolchain.
Dr. Anders Pandya, Chief Scientific Officer of Chipscreen Biosciences, stated:
"Chipscreen Biosciences has always adhered to a research and development philosophy centered on high-quality innovation, continuously exploring technologies and solutions that can enhance drug discovery efficiency. This collaboration with StoneWise integrates its high-performance AI molecular generation model and systematic computational validation capabilities into our early R&D process, which will help further improve the efficiency and precision of early-stage drug development. We look forward to driving continuous breakthroughs in drug R&D through the complementary strengths of both parties."
Zhou Jielong, Chief Executive Officer of StoneWise, commented:
"Chipscreen Biosciences possesses profound drug R&D capabilities and is also one of the earliest pioneers in China to focus on and practice the application of AI in early-stage R&D. We are delighted to partner with such a forward-thinking organization. Through this collaboration, StoneWise's MolVado Platform will serve real-world R&D scenarios more deeply. We aim to provide partners with an efficient and controllable AI Co-pilot for drug R&D through our engineering-driven, deliverable integrated platform capabilities, jointly promoting the sustained and steady implementation of AI in the drug discovery process."
About StoneWise
Founded in 2018, StoneWise is a technology company driving innovative drug R&D through artificial intelligence.
Based on in-depth industry insights into drug R&D, breakthroughs in the underlying theories of AI-driven drug discovery, advanced data governance for drug R&D, and strong software and engineering capabilities, StoneWise has built a small molecule drug design platform anchored by a multimodal AI 3D molecular generation large model. Built on the GPT/Transformer framework and integrated with geometric deep learning algorithms, this model can accurately generate molecules that fit the structure of target pockets, with capabilities that can be transferred to other drug modalities.
Leveraging this platform, the company has achieved significant results in its internal proprietary R&D pipeline, with some programs advancing to clinical trial stages. Additionally, nearly 100 pharmaceutical companies and research institutions have adopted the platform for early-stage drug R&D.
As a foundation model, it allows partners to fully integrate their own data, expertise, and models for customized iterations. Meanwhile, the entity library business derived from the foundation model is actively expanding both domestically and internationally.
Contact Us:
Business Cooperation: bd@stonewise.cn
Investment Inquiries: ir@stonewise.cn
Media Relations: pr@stonewise.cn
